Table 3.
Overall survival due to HRD status in patients with locally advanced or metastatic pancreatic cancer not treated with platinum-based chemotherapy
| Study | HRD | Non-HRD | P value | ||
| n | Median OS (months) | n | Median OS (months) | ||
| Reiss et al 17 | 11 | 6.1 | 30 | 2.8 | 0.12 |
| Pishvaian et al 29 | 19 | 9.1 | 114 | 14.4 | 0.11 |
| Aung et al 31 | 12 | 8.3 | ND | ND | |
| Golan et al 32 | 21 | 9.0 | ND | ND | |
| Faluyi et al 33 | 6 | 7.3 | ND | ND | |
| Total | 69 | 8.3 | 144 | 12.0 | |
HRD, homologous recombination deficiency; n, number of patients; ND, no data provided.